查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1886902

氘代丁苯那嗪市场规模、占有率、成长及全球产业分析：依类型、应用和地区划分的洞察，以及2024-2032年预测

Deutetrabenazine Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 150 Pages | 商品交期: 请询问到货日

价格

氘代丁苯那嗪市场成长驱动因子

受神经系统疾病诊断率上升和监管审批范围扩大的推动，全球氘代丁苯那嗪市场保持强劲成长势头。 2024年，该市场价值16.9亿美元，预计2025年将成长至20.3亿美元，到2032年将达到54.2亿美元。 2025年至2032年间强劲的复合年增长率（15.1%）反映了应用领域的不断拓展、疾病认知度的提高以及已获批准的VMAT2抑制剂的出色表现。

北美市场占绝对主导地位，2024年占全球市占率的94.08%。这得归功于亨丁顿舞蹈症（HD）和迟发性运动障碍（TD）的高发生率、完善的医疗保健基础设施、持续的宣传活动以及早期的监管审批。氘代丁苯那嗪主要由梯瓦製药工业有限公司以 "AUSTEDO" 品牌销售，目前仍处于专利保护期，这限制了仿製药的竞争，并巩固了梯瓦的市场主导地位。

市场动态

市场推动因素

神经退化性疾病（尤其是亨丁顿舞蹈症和迟发性运动障碍）发生率的持续上升是氘代丁苯那嗪应用的主要推动因素。基因检测的普及、临床意识的提高以及早期诊断的普及使得及时治疗介入成为可能。例如，根据罕见疾病咨询机构2023年的报告，预计北美亨廷顿舞蹈症的盛行率将达到每10万人8.87例，这凸显了需要长期VMAT2抑制剂治疗的患者群体不断扩大。

不断增加的研发投入以及製药业对新製剂开发的重视进一步推动了市场扩张。各大医疗机构在治疗指引中扩大采用氘代丁苯那嗪也促进了其广泛应用。

市场限制因子

儘管应用日益广泛，但生产流程的复杂性正在影响市场成长。氘代过程会减缓药物代谢并提高疗效，但同时也会增加生产成本，使新兴市场难以负担。长期安全性问题也可能阻碍药物的持续治疗应用。

监管壁垒，包括欧洲药品管理局 (EMA) 和美国食品药物管理局 (FDA) 严格的上市后监测要求，延长了新适应症和新剂型的审批流程，延缓了药物的广泛商业化。

市场机会

缓释 (XR) 製剂代表着一个重要的机会。梯瓦製药的 AUSTEDO XR（将于 2024 年 5 月上市）采用每日一次给药的便利方式，有助于提高患者依从性并增加处方量。製药公司也正在利用生命週期管理策略，包括开发新的剂量规格、拓展地域范围以及针对更多神经系统疾病进行扩大的临床试验。

亚太地区，尤其是中国、韩国和印度，由于诊断率的提高和医疗服务可近性的改善，成长潜力依然巨大。 2020年5月，中国国家药品监督管理局（NMPA）批准AUSTEDO上市，显着加速了该地区的扩张。

市场挑战

来自其他VMAT2抑制剂（例如丁苯那嗪（Xenazine）和缬苯那嗪（Ingrezza））的竞争持续给市场带来压力。这些药物的给药方案和副作用各不相同，影响着处方医师的选择和价格竞争。

市场趋势

地域扩张是一个显着的趋势。各公司正在欧洲、亚太和拉丁美洲寻求批准和商业合作。策略性专利申请持续保护市场独占权，预计2030年之前不会出现仿製药竞争。

扩大患者权益倡导工作，特别是提高颞颚关节运动障碍（TD）的认知度，也有助于改善诊断和治疗的普及。此外，对更广泛的神经系统疾病适应症（例如妥瑞氏症）的临床投资，预示着未来的成长机会。

市场区隔分析

依应用领域

  • 由于迟发性运动障碍（TD）的高发病率和不断提高的认知度，预计到2024年，TD将占最大的市场占有率。美国的 "TD宣传週" 也印证了这个趋势。
  • 由于研发投入的增加以及透过基因检测进行早期诊断的进步，亨廷顿氏症（HD）的市场占有率预计将快速增长。

依通路划分

  • 由于氘代丁苯那嗪属于处方药，预计到2024年，医院药局将占分销管道的大部分占有率。
  • 随着提供神经专科治疗的药局数量增加，零售药局和药局的市占率预计将会扩大。

区域亮点

北美（2024年：15.9亿美元）

由于早期应用、疾病高发、研发投入巨大以及梯瓦製药的强大影响力，该地区在全球占领先地位。在美国，市场需求持续受到宣传活动和先进神经科中心的推动。

欧洲

公共医疗保健支出增加、欧洲药品管理局 (EMA) 的批准以及亨廷顿​​病 (HD) 患病率上升（2023 年每 10 万人中有 6.37 人患病）正在推动该地区的稳步增长。

亚太地区

监管审批的增加、诊断技术的改进以及神经病学护理基础设施的扩展预计将推动该地区的显着增长。

其他地区

由于疾病认知度低和神经病学基础设施不足，成长仍较为温和。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场推动因素
  • 市场阻碍因素
  • 市场机遇
  • 市场趋势

第四章：主要发现

  • 主要疾病的流行病学
  • 主要国家的监管状况
  • 主要国家的报销状况
  • 主要公司的研产品线分析
  • 主要产业趋势（併购、合作等）
  • 主要公司的新产品发布

第五章：全球氘代丁苯那嗪市场分析、洞察与预测（2019-2032）

  • 市场分析、洞察与预测 - 依应用领域划分
    • 亨丁顿舞蹈症
    • 迟发性运动障碍
    • 其他
  • 市场分析、洞察与预测 - 依分销管道划分
    • 医院药房
    • 零售药局和药局
    • 线上药房
  • 市场分析、洞察与预测 - 依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 其他

第六章 北美氘代激动剂市场分析、洞察与预测（2019-2032）

  • 依国家/地区
    • 美国
    • 加拿大

第七章：欧洲氘代烷市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区

第八章：亚太地区氘代烷市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 亚太其他地区

第九章：其他氘代烷市场分析、洞察与预测（2019-2032）

第十章：竞争分析

  • 全球市占率分析（2024）
  • 公司简介
    • 梯瓦製药工业股份有限公司
    • 其他主要参与者
Product Code: FBI113542

Growth Factors of deutetrabenazine Market

The global deutetrabenazine market continues strong upward momentum, driven by rising diagnosis of neurological disorders and broader regulatory approvals. Valued at USD 1.69 billion in 2024, the market is projected to grow to USD 2.03 billion in 2025 and further reach USD 5.42 billion by 2032. A robust CAGR of 15.1% during 2025-2032 reflects expanding applications, increasing disease awareness, and the strong performance of approved VMAT2 inhibitors.

The market is significantly dominated by North America, which accounted for 94.08% of global share in 2024, supported by a high prevalence of Huntington's disease (HD) and tardive dyskinesia (TD), strong healthcare infrastructure, ongoing awareness programs, and early regulatory approvals. Deutetrabenazine, primarily commercialized under the brand name AUSTEDO by Teva Pharmaceutical Industries Ltd., remains patent-protected, limiting generic competition and strengthening Teva's market dominance.

Market Dynamics

Market Growth Drivers

Rising cases of neurodegenerative disorders-especially HD and TD-remain the strongest driver for deutetrabenazine adoption. Greater access to genetic testing, improved clinical awareness, and early diagnosis enable timely therapeutic intervention. For instance, the Rare Disease Advisory reported in 2023 that HD prevalence in North America reached 8.87 per 100,000 population, highlighting the growing patient pool requiring long-term VMAT2 inhibitor therapy.

Increasing research investments and pharmaceutical focus on new formulations further support market expansion. Broader acceptance of deutetrabenazine in treatment guidelines across major healthcare systems is also fueling uptake.

Market Restraints

Despite rising adoption, market growth is affected by manufacturing complexities. The deuteration process, which slows drug metabolism and enhances efficacy, also increases production costs-reducing affordability in emerging markets. Long-term safety concerns may also hinder sustained therapy use.

Regulatory hurdles, including rigorous EMA and FDA post-marketing surveillance requirements, extend approval timelines for new indications and formulations, delaying broader commercialization.

Market Opportunities

A major opportunity lies in extended-release (XR) formulations. Teva's AUSTEDO XR, launched in May 2024, introduced once-daily dosing convenience, improving patient adherence and supporting prescription growth. Pharmaceutical companies are also leveraging lifecycle management strategies, including new dosing strengths, geographic expansion, and broader clinical trials targeting additional neurological disorders.

Growth potential in Asia Pacific, particularly in China, South Korea, and India, remains strong due to rising diagnosis rates and increasing accessibility. China's NMPA approval of AUSTEDO in May 2020 significantly opened the region for expansion.

Market Challenges

Competition from alternative VMAT2 inhibitors such as tetrabenazine (Xenazine) and valbenazine (Ingrezza) presents ongoing market pressure. These drugs offer different dosing regimens and side-effect profiles, influencing prescriber preference and pricing competition.

Market Trends

A prominent trend is geographical expansion, with companies pushing for approvals and commercial partnerships across Europe, Asia Pacific, and Latin America. Strategic patent filings continue to protect market exclusivity, with generic competition unlikely before 2030.

Growing patient advocacy campaigns-especially regarding TD awareness-are also improving diagnosis and boosting treatment adoption. Additionally, clinical investments targeting broader neurological indications like Tourette syndrome present future growth opportunities.

Segmentation Analysis

By Application

  • Tardive Dyskinesia (TD) held the largest share in 2024 due to high prevalence and growing awareness. TD Awareness Week in the U.S. underscores this trend.
  • Huntington's Disease (HD) is expected to grow rapidly due to rising R&D efforts and earlier diagnosis through genetic testing.

By Distribution Channel

  • Hospital pharmacies dominated in 2024 given the prescription-only status of deutetrabenazine.
  • Retail pharmacies & drug stores are expected to expand as more pharmacies stock specialty neurological drugs.

Regional Highlights

North America (USD 1.59 billion in 2024)

The region leads globally due to early adoption, high disease prevalence, substantial R&D spending, and strong presence of Teva Pharmaceuticals. The U.S. continues to drive market demand supported by awareness programs and advanced neurology centers.

Europe

Rising public healthcare spending, EMA approvals, and growing prevalence of HD (6.37 per 100,000 individuals in 2023) contribute to the region's steady expansion.

Asia Pacific

The region is poised for significant growth due to increasing regulatory approvals, better diagnostics, and expanding neurological care infrastructure.

Rest of World

Growth remains modest due to lower disease awareness and limited neurology infrastructure.

Conclusion

The deutetrabenazine market's rise-from USD 1.69 billion in 2024 to a projected USD 5.42 billion by 2032-shows strong momentum fueled by increasing diagnosis of neurodegenerative disorders, introduction of XR formulations, and robust expansion efforts by Teva. Continued regulatory approvals and clinical innovations will remain central to future market growth.

Segmentation By Application

  • Huntington's Disease
  • Tardive Dyskinesia
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies & Drug Stores
  • Online Pharmacies

By Region

  • North America (By Application, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Application, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific (By Application, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia Pacific
  • Rest of the World (By Application and Distribution Channel)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Epidemiology of Key Diseases
  • 4.2. Regolatory Scenario, By Key Countries/Regions
  • 4.3. Reimbursement Scenario, By Key Countries/Regions
  • 4.4. Pipeline Analysis, By Key Players
  • 4.5. Key Industry Developments (Mergers, Acquisitions, and Collaborations etc.)
  • 4.6. New Product Launches, By Key Players

5. Global Deutetrabenazine Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Application
    • 5.1.1. Huntington's Disease
    • 5.1.2. Tardive Dyskinesia
    • 5.1.3. Others
  • 5.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.2.1. Hospital Pharmacies
    • 5.2.2. Retail Pharmacies & Drug Stores
    • 5.2.3. Online Pharmacies
  • 5.3. Market Analysis, Insights and Forecast - By Region
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. Asia Pacific
    • 5.3.4. Rest of the World

6. North America Deutetrabenazine Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Application
    • 6.1.1. Huntington's Disease
    • 6.1.2. Tardive Dyskinesia
    • 6.1.3. Others
  • 6.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.2.1. Hospital Pharmacies
    • 6.2.2. Retail Pharmacies & Drug Stores
    • 6.2.3. Online Pharmacies
  • 6.3. Market Analysis, Insights and Forecast - By Country
    • 6.3.1. U.S.
    • 6.3.2. Canada

7. Europe Deutetrabenazine Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Application
    • 7.1.1. Huntington's Disease
    • 7.1.2. Tardive Dyskinesia
    • 7.1.3. Others
  • 7.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.2.1. Hospital Pharmacies
    • 7.2.2. Retail Pharmacies & Drug Stores
    • 7.2.3. Online Pharmacies
  • 7.3. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.3.1. K.
    • 7.3.2. Germany
    • 7.3.3. France
    • 7.3.4. Spain
    • 7.3.5. Italy
    • 7.3.6. Rest of Europe

8. Asia Pacific Deutetrabenazine Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Application
    • 8.1.1. Huntington's Disease
    • 8.1.2. Tardive Dyskinesia
    • 8.1.3. Others
  • 8.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.2.1. Hospital Pharmacies
    • 8.2.2. Retail Pharmacies & Drug Stores
    • 8.2.3. Online Pharmacies
  • 8.3. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.3.1. Japan
    • 8.3.2. China
    • 8.3.3. India
    • 8.3.4. Australia
    • 8.3.5. Rest of Asia Pacific

9. Rest of the World Deutetrabenazine Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Application
    • 9.1.1. Huntington's Disease
    • 9.1.2. Tardive Dyskinesia
    • 9.1.3. Others
  • 9.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.2.1. Hospital Pharmacies
    • 9.2.2. Retail Pharmacies & Drug Stores
    • 9.2.3. Online Pharmacies

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2024)
  • 10.2. Company Profiles
    • 10.2.1. Teva Pharmaceutical Industries Ltd.
      • 10.2.1.1. Overview
      • 10.2.1.2. Products & services
      • 10.2.1.3. SWOT Analysis
      • 10.2.1.4. Recent Developments
      • 10.2.1.5. Strategies
      • 10.2.1.6. Financials (Based on Availability)
    • 10.2.2. Other Prominent Players
      • 10.2.2.1. Overview
      • 10.2.2.2. Products & services
      • 10.2.2.3. SWOT Analysis
      • 10.2.2.4. Recent Developments
      • 10.2.2.5. Strategies
      • 10.2.2.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Deutetrabenazine Market Revenue (USD billion) Forecast, By Application, 2019-2032
  • Table 2: Global Deutetrabenazine Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
  • Table 3: Global Deutetrabenazine Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 4: North America Deutetrabenazine Market Revenue (USD billion) Forecast, By Application, 2019-2032
  • Table 5: North America Deutetrabenazine Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
  • Table 6: North America Deutetrabenazine Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 7: Europe Deutetrabenazine Market Revenue (USD billion) Forecast, By Application, 2019-2032
  • Table 8: Europe Deutetrabenazine Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
  • Table 9: Europe Deutetrabenazine Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 10: Asia Pacific Deutetrabenazine Market Revenue (USD billion) Forecast, By Application, 2019-2032
  • Table 11: Asia Pacific Deutetrabenazine Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
  • Table 12: Asia Pacific Deutetrabenazine Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 13: Rest of the World Deutetrabenazine Market Revenue (USD billion) Forecast, By Application, 2019-2032
  • Table 14: Rest of the World Deutetrabenazine Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032

List of Figures

  • Figure 1: Global Deutetrabenazine Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global Deutetrabenazine Market Value Share (%), By Application, 2024 & 2032
  • Figure 3: Global Deutetrabenazine Market Value Share (%), By Distribution Channel, 2024 & 2032
  • Figure 4: Global Deutetrabenazine Market Value (USD billion), by Region, 2024 & 2032
  • Figure 5: North America Deutetrabenazine Market Value (USD billion), By Application, 2024 & 2032
  • Figure 6: North America Deutetrabenazine Market Value Share (%), By Application, 2024
  • Figure 7: North America Deutetrabenazine Market Value (USD billion), By Distribution Channel, 2024 & 2032
  • Figure 8: North America Deutetrabenazine Market Value Share (%), By Distribution Channel, 2024
  • Figure 9: North America Deutetrabenazine Market Value (USD billion), By Country, 2024 & 2032
  • Figure 10: North America Deutetrabenazine Market Value Share (%), By Country, 2024
  • Figure 11: Europe Deutetrabenazine Market Value (USD billion), By Application, 2024 & 2032
  • Figure 12: Europe Deutetrabenazine Market Value Share (%), By Application, 2024
  • Figure 13: Europe Deutetrabenazine Market Value (USD billion), By Distribution Channel, 2024 & 2032
  • Figure 14: Europe Deutetrabenazine Market Value Share (%), By Distribution Channel, 2024
  • Figure 15: Europe Deutetrabenazine Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 16: Europe Deutetrabenazine Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 17: Asia Pacific Deutetrabenazine Market Value (USD billion), By Application, 2024 & 2032
  • Figure 18: Asia Pacific Deutetrabenazine Market Value Share (%), By Application, 2024
  • Figure 19: Asia Pacific Deutetrabenazine Market Value (USD billion), By Distribution Channel, 2024 & 2032
  • Figure 20: Asia Pacific Deutetrabenazine Market Value Share (%), By Distribution Channel, 2024
  • Figure 21: Asia Pacific Deutetrabenazine Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 22: Asia Pacific Deutetrabenazine Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 23: Rest of the World Deutetrabenazine Market Value (USD billion), By Application, 2024 & 2032
  • Figure 24: Rest of the World Deutetrabenazine Market Value Share (%), By Application, 2024
  • Figure 25: Rest of the World Deutetrabenazine Market Value (USD billion), By Distribution Channel, 2024 & 2032
  • Figure 26: Rest of the World Deutetrabenazine Market Value Share (%), By Distribution Channel, 2024
  • Figure 27: Global Deutetrabenazine Market Share (%), By Company, 2024